NERV
Minerva Neurosciences, Inc.
There isn't enough reported data to score NERV yet.
NERV Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Strong |
NERV's balance sheet is currently strong, but its revenue and profitability are weak. There isn't enough data to rate its cash flow.
NERV PE Valuation
NERV has no meaningful PE right now: it lost money over the past year.
NERV Forward outlook
There aren't enough analyst estimates for NERV to show an outlook.
NERV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$36.57 | -$34.72 |
| Q2 2026 | -$36.74 | -2582% |
| Q1 2026 | -$37.03 | -4616% |
| Q4 2025 | -$34.67 | -18347% |
| Q3 2025 | -$1.85 | -$1.45 |
| Q2 2025 | $1.48 | +$5.88 |
| Q1 2025 | $0.82 | +$5.25 |
| Q4 2024 | $0.19 | +$4.80 |
NERV lost $36.57 per share over the past year, a bigger loss than the year before.
NERV Quarterly Revenue
NERV's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2020 | 72% | N/A |
NERV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.1M | -$5.2M |
| Q2 2026 | -$13.3M | -$11.3M |
| Q1 2026 | -$5.4M | -$1.4M |
| Q4 2025 | -$4.5M | +$686K |
| Q3 2025 | -$2.9M | +$1.4M |
| Q2 2025 | -$2M | +$1.9M |
| Q1 2025 | -$4.1M | +$2M |
| Q4 2024 | -$5.2M | +$824.6K |
NERV has burned cash in almost every quarter: −$31M over the past year, against −$14M the year before.
NERV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.9% | -3.9M shares |
| 1 year | +894% | +67.7M shares |
| 3 years | +894% | +67.7M shares |
| 5 years | +1309% | +69.9M shares |
| Available history | +1443% | +70.4M shares |
NERV has 75M diluted shares, up 894% from a year ago.
NERV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | -13.6x | Net Cash |
NERV has more cash than debt.
NERV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 11.3 | Oversold |
NERV's weekly RSI is 31 (neutral) and its Stochastic is 11 (oversold).
NERV PE vs Healthcare Sector
| Metric | NERV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NERV has no meaningful PE right now: it lost money over the past year.
NERV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.70 | 12% below |
| 20 week MA | $3.73 | 36% below |
| 50 week MA | $4.65 | 49% below |
| 100 week MA | $3.42 | 30% below |
| 200 week MA | $4.02 | 41% below |
NERV is in a downtrend: it's below all five of its weekly moving averages, and 41% below its 200-week average.
NERV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.2 | $19.7 | -64% |
| 2021 | $19.7 | $7.72 | -61% |
| 2022 | $7.72 | $2.48 | -68% |
| 2023 | $2.48 | $6.15 | +148% |
| 2024 | $6.15 | $2.26 | -63% |
| 2025 | $2.26 | $4.19 | +85% |
| 2026 YTD | $4.19 | $2.38 | -43% |
NERV's yearly returns have swung widely, from +148% in 2023 to −68% in 2022. It's down 43% so far in 2026.